Posted by Michael Wonder on 15 Apr 2020
Review of cancer drug benefits delayed amid social distancing
8 April 2020 - The government has postponed the health authorities’ meeting for a review of anticancer drugs’ benefits initially scheduled for Wednesday to minimise the risk of the spread of the new coronavirus in a face-to-face meeting.
The Health and Insurance Review and Assessment Service (HIRA) said it had planned to hold the deliberation of the Review Committee for Cancer Diseases in late February but put off the schedule to Wednesday.
The review committee consists of 43 cancer experts at various medical institutions.
